Universität zu Köln

Eichenauer, Dennis A., Eich, Hans Theodor and Engert, Andreas (2022). Treatment of nodular lymphocyte-predominant Hodgkin lymphoma. Onkologie, 28 (10). S. 908 - 914. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Full text not available from this repository.

Abstract

Background Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma (HL) cases. Pathological characteristics, clinical course and treatment in part differ from classical HL (cHL). Aim The present article gives an overview of current treatment options for NLPHL. Materials and methods A selective literature review was performed. Results In contrast to cHL, the malignant cells in NLPHL consistently express CD20 but are negative for CD30. Patients with newly diagnosed stage IA NLPHL without clinical risk factors are usually treated with radiotherapy alone. In relapsed disease, high-dose chemotherapy followed by autologous stem cell transplantation is only required in a minority of cases, whereas anti-CD20 antibody treatment or conventional chemotherapy are mostly sufficient. In newly diagnosed NLPHL other than stage IA without clinical risk factors, treatment is often very similar to cHL. However, protocols used in B-cell non-Hodgkin lymphoma (B-NHL) are also active. Some patients with a history of NLPHL develop histological transformation into aggressive B-NHL during follow-up. The 10-year transformation rate is roughly 10%. Therefore, obtaining a biopsy is mandatory if relapse is suspected. Overall, NLPHL has a very good prognosis with an 8-year survival rate exceeding 90%. Conclusion NLPHL is a rare subtype of HL that differs from cHL in several respects. Stage-adapted therapy usually leads to long-term remission. The therapy of NLPHL differs from that of cHL in some situations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eich, Hans Theodor UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-668173
DOI:	10.1007/s00761-022-01154-3
Journal or Publication Title:	Onkologie
Volume:	28
Number:	10
Page Range:	S. 908 - 914
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	2731-7234
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language LONG-TERM; TRANSFORMATION; RITUXIMAB; PHASE-2 Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66817